National Eye Institute

Resolve patient confusion with AMD awareness, understandingAge-related macular degeneration (AMD) is the leading cause of significant visual acuity loss in people over the age of 50 in developed countries. Almost 80% of the people diagnosed with AMD will have the non-neovascular (dry) or atrophic subtypes. Here is the clinical information patients need to understand this disease.
Are you aware of the available resources for AMD?Since February is designated Age-Related Macular Degeneration Awareness month. For healthcare providers, there are numerous resources available to help promote awareness to patients and to encourage patients to continue (or start) annual visual exams.
Schepens lecturer traces advent, evolution of ophthalmic trialsClinical trials are an indispensable ordeal that are the gold standard for assessing risks and benefits of treatments, said Frederick L. Ferris III, MD.
Precision medicine coming to glaucoma via specific pathwaysCharacterizing the genetic elements linked to different types of glaucoma, such as in the Primary Open-Angle African American Glaucoma Genetics study, could help clinicians develop more precise and effective treatments.
Unmasking retinal structure, function in X-linked retinoschisis“There is a compelling need to explore gene therapy in the eye,” according to Paul A. Sieving, MD, PhD.
Sunlight and its effect on eye healthAvoiding sunlight entirely appears to be a misdirection. Melanoma is inversely related to latitude and inadequate acclimation (i.e., increased melanization and epidermal thickening), which carries the risk of both melanoma and non-melanoma skin cancer—common in northern latitudes.
Aggressive blood sugar control slows diabetic eye disease progressionNIH-funded study shows less diabetic retinopathy progression among those who underwent intensive glycemic control.
Getting ready for ARVO 2017: New president, special OCT issueLearn about the latest updates from The Association for Research in Vision and Ophthalmology for 2017 and beyond.
New approaches and technologies offer hope in vision restorationNew agents and devices offer promise to control IOP and slow, perhaps even stop, the advancing vision loss that is common in glaucoma. Research and development to restore vision is starting to show significant results in preclinical models and early stage clinical trials.
New prevention and monitoring strategies for neovascular AMDNutritional supplements continue to be a viable prevention strategy for neovascular age-related macular degeneration (AMD), said Emily Chew, MD.